RELCA: a REgional Life Cycle inventory for Assessing bioenergy systems within a region

Background: The last decade has seen major development and adoption of bioenergy, particularly in Germany. This has resulted in a scattering of decentralised bioenergy plants across the landscape, due to their dependency on spatially diffuse biomass resources. Regional conditions (e.g., soils, climate, management) influence the environmental burdens resulting from biomass production and thus, also effect the environmental performance of bioenergy production. Therefore, more regionally focused life cycle approaches are required for assessing these bioenergy systems. The aim of this paper is to outline such an approach. “RELCA”, is a regional life cycle inventory for assessing the regional and spatial variation in the environmental performance of bioenergy production within a region. Methods: Five modelling steps are combined to form the RELCA approach in order to determine: (1) regional crop allocation, (2) regional biomass management, (3) representative bioenergy plant models, (4) bioenergy plant catchments, and (5) indirect upstream emissions (non-regional) associated with regional bioenergy production. The challenges and options for each of these five modelling steps are outlined. Additionally, a simple example is provided using greenhouse gases emissions (GHG) to show how RELCA can be used to identify the potential regional distribution of environmental burdens associated with the production of a bioenergy product (e.g. biodiesel) within a region. Results: An approach for combining regionally distributed inventory for biomass production with regionally distributed inventory for bioenergy technologies, through the use of catchment delineation was developed. This enabled the introduction of greater regional details within the life cycle approach. As a first “proof of concept,” GHG emissions were estimated for a simple example, illustrating how RELCA can identify the potential regional distribution of environmental burdens (direct and indirect) associated with producing a bioenergy product. Conclusions: RELCA (v1.0) is a powerful scoping approach, which is the first to investigate the regional and spatial variation in the environmental performance of bioenergy production within a region through the use of catchment delineation. RELCA (v1.0) is not without its limitations. Despite these, it still provides a good starting point for further discussion, improvements, and modelling developments for assessing the regional and spatial environmental implications of bioenergy production (e.g., such as impacts to soil, water, and biodiversity) for a within regional context

Inducible Presynaptic Glutamine Transport Supports Glutamatergic Transmission at the Calyx of Held Synapse

he mechanisms by which the excitatory neurotransmitter glutamate is recycled at synapses are currently unknown. By examining the functional expression of plasma membrane transporters at presynaptic terminals, we aim to elucidate some of the mechanisms of glutamate recycling. Using whole-cell voltage-clamp recordings from rat calyx of Held presynaptic terminals, our data show, for the first time, that the glutamate precursor glutamine causes the direct activation of an electrogenic, sodium-dependent presynaptic transporter, which supplies glutamine for generation of presynaptic glutamate and helps sustain synaptic transmission. Interestingly, the functional expression of this transporter at the presynaptic plasma membrane is dynamically controlled by electrical activity of the terminal, indicating that uptake of neurotransmitter precursors is controlled by the demand at an individual terminal. Induction of the transporter current is calcium-dependent and inhibited by botulinum neurotoxin C, demonstrating the involvement of SNARE-dependent exocytosis in inserting transporters into the plasma membrane when the terminal is active. Conversely, inactivity of the presynaptic terminal results in removal of transporters via clathrin-mediated endocytosis. To investigate whether the presynaptic glutamine transporter supplies the precursor for generating the synaptically released glutamate, we measured miniature EPSCs to assess vesicular glutamate content. When the presynaptic glutamate pool was turned over by synaptic activity, inhibiting the presynaptic glutamine transporters with MeAIB reduced the miniature EPSC amplitude significantly. This demonstrates that presynaptic glutamine transport is centrally involved in the production of glutamate and assists in maintaining excitatory neurotransmission. © 2013 the authors

Disciplinary Social Policy and the Failing Promise of the New Middle Classes: The Troubled Families Programme

This article looks at the promise of the ‘New Middle Class’ (NMC) inherent in the neoliberal ideological ideal of individualising societal responsibility for well-being and success. The article points to how this promise enables a discourse and practice of welfare reform and a disciplining of life styles particularly targeting the very poor in society. Women and some ethnic minorities are particularly prone to poverty and then therefore also discipline. The article then provides a case study of the Troubled Families Programme (TFP) and shows how the programme and the way it is constructed and managed partly undermines the provision of the material needs to alleviate people from poverty and re-produces discourses of poor lifestyle and parenting choices as sources of poverty, thereby undermining the ‘middle-class’ promise

In Vitro and in Vivo Anti-Inflammatory Activity of the New Glucocorticoid Ciclesonide

ABSTRACT The glucocorticoid ciclesonide is the 2ЈR-epimer of 2Ј-cyclohexyl-11␤-hydroxy-21-isobutyryloxy-16bH-dioxolo [5Ј,4Ј:16,17]pregna-1,4-diene-3,20-dione. The active metabolite desisobutyrylciclesonide (des-CIC) is derived from ciclesonide by esterase cleavage of isobutyrate at the C21 position. The relative binding affinities at the rat glucocorticoid receptor were dexamethasone, 100; ciclesonide, 12; des-CIC, 1212; and budesonide, 905. Des-CIC potently inhibited the activation of murine and human lymphocytes in a series of different in vitro systems. With the exception of concanavalin A-stimulated rat spleen cells, des-CIC was more potent than the parent compound. Des-CIC compared well with budesonide in all in vitro systems. Furthermore, the respective 2ЈS-epimers were always significantly less potent than the 2ЈR-epimers. In vivo, ciclesonide (intratracheal administration), des-CIC, and budesonide inhibited antigen-induced accumulation of eosinophils, protein, and tumor necrosis factor-␣ into the bronchoalveolar lavage fluid of ovalbumin-sensitized and -challenged Brown Norway rats with an ED 50 value ranging from 0.4 to 1.3 mg/kg, indicating similar potency, which suggests in vivo activation of the parent compound. Ciclesonide and budesonide inhibited the bradykinin-induced protein leakage into the rat trachea. In the rat cotton pellet model, ciclesonide inhibited granuloma formation (ED 50 :ϭ of 2 g/pellet), whereas budesonide and des-CIC were 15-and 20-fold less active; thymus involution was induced with an ED 50 of 303, 279, and 154 g/pellet, respectively. When applied orally to rats for 28 days, ciclesonide showed low potency in reducing weight of thymus and adrenals, suggesting low oral bioavailability. The in vivo data on ciclesonide highlight its effective local action and a reduced potential for side effects

Identification and Characterization of Six Spectroscopically Confirmed Massive Protostructures at 2.5<z<4.52.5<z<4.5

We present six spectroscopically confirmed massive protostructures, spanning a redshift range of $2.5<z<4.5$ in the Extended Chandra Deep Field South (ECDFS) field discovered as part of the Charting Cluster Construction in VUDS and ORELSE (C3VO) survey. We identify and characterize these remarkable systems by applying an overdensity measurement technique on an extensive data compilation of public and proprietary spectroscopic and photometric observations in this highly studied extragalactic field. Each of these six protostructures, i.e., a large scale overdensity (volume $>9000$\thinspace cMpc$^3$) of more than $2.5\sigma_{\delta}$ above the field density levels at these redshifts, have a total mass $M_{tot}\ge10^{14.8}M_\odot$ and one or more highly overdense (overdensity$\thinspace>5\sigma_{\delta}$) peaks. One of the most complex protostructures discovered is a massive ($M_{tot}=10^{15.1}M_\odot$) system at $z\sim3.47$ that contains six peaks and 55 spectroscopic members. We also discover protostructures at $z\sim3.30$ and $z\sim3.70$ that appear to at least partially overlap on sky with the protostructure at $z\sim3.47$, suggesting a possible connection. We additionally report on the discovery of three massive protostructures at $z=2.67$, 2.80, and 4.14 and discuss their properties. Finally, we discuss the relationship between star formation rate and environment in the richest of these protostructures, finding an enhancement of star formation activity in the densest regions. The diversity of the protostructures reported here provide an opportunity to study the complex effects of dense environments on galaxy evolution over a large redshift range in the early universe.Comment: 10 pages, 4 figures, 1 tabl

Localization and function of the renal calcium-sensing receptor

The ability to monitor changes in the ionic composition of the extracellular environment is a crucial feature that has evolved in all living organisms. The cloning and characterization of the extracellular calcium-sensing receptor (CaSR) from the mammalian parathyroid gland in the early 1990s provided the first description of a cellular, ion-sensing mechanism. This finding demonstrated how cells can detect small, physiological variations in free ionized calcium (Ca 2+) in the extracellular fluid and subsequently evoke an appropriate biological response by altering the secretion of parathyroid hormone (PTH) that acts on PTH receptors expressed in target tissues, including the kidney, intestine, and bone. Aberrant Ca 2+ sensing by the parathyroid glands, as a result of altered CaSR expression or function, is associated with impaired divalent cation homeostasis. CaSR activators that mimic the effects of Ca 2+ (calcimimetics) have been designed to treat hyperparathyroidism, and CaSR antagonists (calcilytics) are in development for the treatment of hypercalciuric disorders. The kidney expresses a CaSR that might directly contribute to the regulation of many aspects of renal function in a PTH-independent manner. This Review discusses the roles of the renal CaSR and the potential impact of pharmacological modulation of the CaSR on renal function

Associations between depressive symptoms and disease progression in older patients with chronic kidney disease: results of the EQUAL study

Background Depressive symptoms are associated with adverse clinical outcomes in patients with end-stage kidney disease; however, few small studies have examined this association in patients with earlier phases of chronic kidney disease (CKD). We studied associations between baseline depressive symptoms and clinical outcomes in older patients with advanced CKD and examined whether these associations differed depending on sex. Methods CKD patients (&gt;= 65 years; estimated glomerular filtration rate &lt;= 20 mL/min/1.73 m(2)) were included from a European multicentre prospective cohort between 2012 and 2019. Depressive symptoms were measured by the five-item Mental Health Inventory (cut-off &lt;= 70; 0-100 scale). Cox proportional hazard analysis was used to study associations between depressive symptoms and time to dialysis initiation, all-cause mortality and these outcomes combined. A joint model was used to study the association between depressive symptoms and kidney function over time. Analyses were adjusted for potential baseline confounders. Results Overall kidney function decline in 1326 patients was -0.12 mL/min/1.73 m(2)/month. A total of 515 patients showed depressive symptoms. No significant association was found between depressive symptoms and kidney function over time (P = 0.08). Unlike women, men with depressive symptoms had an increased mortality rate compared with those without symptoms [adjusted hazard ratio 1.41 (95% confidence interval 1.03-1.93)]. Depressive symptoms were not significantly associated with a higher hazard of dialysis initiation, or with the combined outcome (i.e. dialysis initiation and all-cause mortality). Conclusions There was no significant association between depressive symptoms at baseline and decline in kidney function over time in older patients with advanced CKD. Depressive symptoms at baseline were associated with a higher mortality rate in men